Tirzepatide
Product Details
Tirzepatide — Research Peptide
Tirzepatide is a synthetic peptide commonly studied in laboratory settings for its interaction with glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor signaling pathways. As a dual incretin receptor agonist, Tirzepatide has been investigated for its role in metabolic signaling, endocrine communication mechanisms, and peptide-mediated regulatory pathways.
Scientific literature has explored Tirzepatide in studies involving incretin signaling, glucose regulation pathways, metabolic homeostasis, and receptor-mediated cellular communication. Additional research has examined how dual agonist peptides interact with endocrine signaling systems associated with energy balance and metabolic pathway regulation.
Published studies have investigated Tirzepatide in laboratory models involving GLP-1 and GIP receptor activity, peptide-receptor interactions, biochemical signaling pathways, and metabolic communication systems. Research has also explored its role in endocrine signaling and molecular pathway analysis related to metabolic regulation.
This compound is supplied for qualified laboratory research and analytical purposes only.
Product Details
Product Name: Tirzepatide
Form: Lyophilized peptide powder
Grade: Research use only
Application: Laboratory research and analytical testing only
Storage: Store in a cool, dry place under proper laboratory storage conditions.
Research Areas
This compound may be used in research related to:
- GLP-1 and GIP receptor signaling studies
- Metabolic and endocrine pathway research
- Incretin signaling and receptor activity investigation
- Peptide-mediated cellular communication analysis
- Energy regulation and metabolic homeostasis studies
- Biochemical and molecular signaling research
- Cellular metabolism and endocrine pathway investigation
Research References
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” New England Journal of Medicine.
- Frias JP, Nauck MA, Van J, et al. “Efficacy and safety of tirzepatide versus semaglutide.” The Lancet.
- Campbell JE, Drucker DJ. “Pharmacology, physiology, and mechanisms of incretin hormone action.” Cell Metabolism.
Lorem ipsum dolor ist amte, consectetuer adipiscing eilt. Aenean commodo ligula egget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Donec quak felis, ultricies nec, pellentesque eu, pretium quid, sem.
